-
-
About PMI
- Welcome to PMI Science
- PMI Science Booklet
- Our Scientists
- The Cube: PMI’s R&D Center
- PMI’s Global Network
- Facts and Figures
About PMIExplore PMI Science, where innovation meets harm reduction. Learn about our scientists, smoke-free research, and commitment to transparency in research.Read More -
Smoke-free approach
- Harm Reduction
- Absence of Combustion
- Nicotine
- Cigarette Tar
- Tobacco regulation
- Harmful Chemicals Measured
Smoke-free approachPMI offers smoke-free alternatives with the potential to reduce the risk of harm for adult smokers who do not quit. Learn about harm reduction, the role of nicotine, and the regulation of smoke-free products.Read More -
Research
- PMI’s studies on smoke-free products
- Our findings
- PMI Publications Library
- Literature reviews
- Independent studies
- Investigator Initiated Studies
ResearchDiscover PMI's rigorous scientific approach to smoke-free products and product assessment. Dive into our research results, peer-reviewed publications, independent research, and expert reports.Read More -
Our Products
- Heated tobacco products
- E-cigarettes and vaping products
- Nicotine pouches
- Nicotine Salts Product
Our ProductsPMI believes that offering a range of smoke-free alternatives is essential to ensure individual smokers are able to find a smoke-free product that they can fully switch to.Read More -
News & Events
- Scientific Update magazine
- Open Science events
- News
- Conferences calendar
News & EventsExplore the latest insights and stay informed about upcoming events and conference presentations from PMI scientists.Read More - Contact Us
-
About PMI
Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes
A Single-center, Randomized, Controlled, Open-label, Cross-over Study in Healthy Subjects to Investigate the Nicotine Pharmacokinetic Profiles of 2 Variants of P4M3 Gen 2.0, an Electronic Nicotine Delivery System, Compared to Cigarettes
This is a single-center, randomized, controlled, open-label, cross-over study with healthy adult smokers. The study will investigate the nicotine pharmacokinetic (PK) profiles of two e-liquid variants used with the P4M3 Gen 2.0 e-cigarette, compared to smoking combustible cigarettes. In addition, pharmacodynamic (PD) effects (subjective effects and related behavioral assessments), will be evaluated to provide further insights on product evaluation, craving, liking, puffing topography. The study will be conducted with three periods and six sequences in a cross-over design. This study is exploratory and there is no pre-specified hypothesis to be tested.
Recruitment: Completed
Study Results: No Results Available
Enrollment: 36
Study Type: Interventional
Other IDs: P4-PK-04-US
Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms
Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence
Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking
Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease
Reduced Exposure to HPHC in Smokers Switching From Cigarettes to Different Versions of THS
Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.